samedan logo
 
 
spacer
home > ict > autumn 2017 > end point: a costly cause
PUBLICATIONS
International Clinical Trials

End Point: A Costly Cause

Our sister publication, Pharmafile (in its spring 2017 edition), listed the predicted top 50 selling products in the world in 2022. I was astonished to note that the vast majority of these products are biotechnology-based products rather than traditional molecules. Fewer than 10 small molecules feature on this list. In a separate article, Pharmafile discusses the world of $100,000 products and how this will impact on the future of healthcare. If you examine the list of these drugs a little further, you will note that the majority of them are not for rare conditions, but unusual ones. I remember that while working for the agrochemical industry, a development scientist at one of the leading US companies told me that, if the new pesticide did not work on corn or cotton, it would never make economic sense to develop it. In the same group, a farmer who grew courgettes said ‘What hope have I got for the future then?’ The pharmaceutical industry is not yet in this parlous condition, but it may be that the era of the blockbuster is ending and precision medicine will take its place.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

spacer
Dr Graham Hughes
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

rfxcel Covers the Cost of EMVO Onboarding Fees

May 23, 2018 - San Ramon, CA – rfxcel Corporation, a technically certified Gateway Provider for the European Medicines Verification Organisation (EMVO) announced today that it will pay the cost of statutory fees payable to EMVO* for all manufacturers (Marketing Authorisation Holders, MAHs) which select rfxcel as their Gateway Provider before June 15th 2018.
More info >>

White Papers

Clinical Research in Spain

BioClever

This whitepaper is on clinical research in Spain, giving a general outline of the main characteristics of research in this country and an overview of the applicable regulations, along with the reasons why Spain is a good place to do research.
More info >>

 
Industry Events

SMi presents the 2nd annual conference on Pharmaceutical Microbiology West Coast

6-8 June 2018, Crowne Plaza, San Diego, CA, USA

SMi proudly presents the 2nd Annual Pharmaceutical Microbiology West Coast Conference, in San Diego, USA, on the 7th and 8th of June 2018. Delivering updates and promoting discussion on key challenges and developments within the pharmaceutical microbiology industry.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement